Forte Biosciences (FBRX) Cash from Operations Growth (5y) (2021 - 2026)
Forte Biosciences (FBRX) Cash from Operations Growth (5y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.07% |
| Dec 31, 2025 | -34.09% |
| Sep 30, 2025 | -12.59% |
| Jun 30, 2025 | -20.16% |
| Mar 31, 2025 | -29.30% |
| Dec 31, 2024 | -72.62% |
| Sep 30, 2024 | -71.20% |
| Jun 30, 2024 | -18.82% |
| Mar 31, 2024 | 17.72% |
| Dec 31, 2023 | 5.57% |
| Sep 30, 2023 | -63.22% |
| Jun 30, 2023 | 12.64% |
| Mar 31, 2023 | 16.35% |
| Dec 31, 2022 | 20.61% |
| Sep 30, 2022 | 22.73% |
| Jun 30, 2022 | 28.47% |
| Mar 31, 2022 | 23.56% |
| Dec 31, 2021 | 14.30% |
| Sep 30, 2021 | 8.37% |
| Jun 30, 2021 | 12.74% |